Since its introduction in 2010, the dual mobility segment has grown rapidly, and today 9 percent of primary hip arthroplasty procedures and 28 percent of revisions in the American Joint Registry utilized a dual mobility device.2
OR3O incorporates Smith+Nephew's latest advanced bearing surface, OXINIUM DH (Diffusion Hardened), for its liner as well as its proprietary VERILAST Technology for its femoral head and polyethylene inserts. OXINIUM Technology has been shown to deliver significant reductions in wear compared to Cobalt Chrome (CoCr), the material used in most competitive products.3
"The OR3O Dual Mobility System is truly a fourth generation dual mobility offering by introducing OXINIUM technologies. This is a solution that allows patients to get back to their lives by providing stability and offers advantages compared to other systems," said Stephen Duncan, M.D., an orthopedic surgeon at the University of Kentucky.
"Our new OR3O Dual Mobility System is a groundbreaking product that offers technology not available in competitive systems," said Skip Kiil, president of Orthopaedics at Smith+Nephew. "The proven success of our VERILAST Technology and OXINIUM DH bearing surface set OR3O apart as a game-changing solution in the hip arthroplasty market."
OXINIUM DH is the newest addition to Smith+Nephew's OXINIUM platform and increases the depth of hardening through a patented technology process. It is designed specifically to address hip arthroplasty needs.
Smith+Nephew's OR3O Dual Mobility System is available in the United States for both primary and revision applications and offers cross-compatibility with the R3 and REDAPT acetabular systems.
Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. Its more than 16,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management, and Sports Medicine & ENT. Founded in Hull, U.K., in 1856, the company now operates in more than 100 countries, and generated annual sales of $4.9 billion in 2018. Smith+Nephew is a constituent of the FTSE100. The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries.
1 Darrith B, Courtney P.M., Della Valle C.J. Outcomes of dual mobility components in total hip arthroplasty. Bone Joint J 2018;100-B:11–19.
2 Heckmann N, Ihn H, Stefl M, et al. Early Results From the American Joint Replacement Registry: A Comparison With Other National Registries. Journal of Arthroplasty. 2019;34(7, Suppl):S125-34.e1
3 Parikh A, Hill P, Pawar V, Sprague J. Long-term simulator wear performance of an advanced bearing technology for THA. Poster: 1028. ORS 2013.